IRIS

n-Hexane

CASRN 110-54-3

Health Hazard Assessments for Effects Other than Cancer

Reference Dose for Oral Exposure (RfD) (PDF) (28 pp, 188 K) last updated: 12/23/2005
Not assessed under the IRIS Program.

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (28 pp, 188 K) last updated: 12/23/2005

System RfC (mg/m3) Basis PoD Composite UF Confidence
Nervous 7 x 10-1 Peripheral neuropathy (decreased MCV at 12 weeks) BMCL (HEC): 215
mg/m3
300 Medium

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (28 pp, 188 K) last updated: 12/23/2005

WOE Characterization Framework for WOE Characterization
Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Under the emGuidelines for Carcinogen Risk Assessment/em (U.S. EPA, 2005b), there is eminadequate information to assess the carcinogenic potential of n-hexane./em
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (28 pp, 188 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (28 pp, 188 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.